Drug intelligence / Profile preview

lanerkitug

Development stage: Phase 1
Lead developer: Bayer
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Lanerkitug is a human immunoglobulin G1 (IgG1) monoclonal antibody that targets the C-C chemokine receptor type 8 (CCR8). It is afucosylated to enhance its immune effector functions, particularly antibody-dependent cell-mediated cytotoxicity (ADCC). The drug acts as an inhibitor of CCR8, which is expressed on regulatory T lymphocytes (Tregs) within the tumor microenvironment. By blocking CCR8 and depleting Tregs via ADCC, lanerkitug aims to modulate the immune response against tumors and exert antineoplastic effects. Lanerkitug is being developed primarily for the treatment of advanced solid tumors, including melanoma and non-small cell lung cancer. The developer of this drug is Bayer[2][3][4].

Other names: lanerkitug

Targets

CCR8

Beyond the preview

Go deeper on lanerkitug.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lanerkitug.

Explore the full profile